Nasdaq

Apogee Therapeutics Reports Positive Interim Phase 1 Results for APG990, Featuring 60-Day Half-Life and Plans for Head-to-Head Trial Against DUPIXENT

Apogee Therapeutics, Inc. announced positive interim Phase 1 results for its novel OX40L antibody, APG990, which demonstrated a half-life of approximately 60 days and potential for infrequent dosing.
Nasdaq

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis ...

Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO ...
Seeking Alpha

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

SAN FRANCISCO and BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for ...
Benzinga.com

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

On Monday, Apogee Therapeutics, Inc. (NASDAQ:APGE) released interim Phase 1 results from its first-in-human trial of APG990. APG990 interim Phase 1 pharmacokinetic (PK) data showed a half-life of ...
Enid News & Eagle

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its ...

The APG333 Phase 1 clinical trial is designed as a double-blind, placebo controlled, first-in-human, single-ascending dose trial in healthy volunteers. The study will evaluate the safety, tolerability ...